PROVECTUS BIOPHARMACEUTICALS, INC.: 10-Q filed 2022-11-09

Name: PROVECTUS BIOPHARMACEUTICALS, INC.: 10-Q filed 2022-11-09
Creator: PROVECTUS BIOPHARMACEUTICALS, INC.

What PROVECTUS BIOPHARMACEUTICALS, INC. reported in its quarterly report filed 2022-11-09 (fiscal Q3 2022): 30 published measures, 88 facts as tagged in accession 0001493152-22-031108.

This filing

Form: 10-Q (quarterly report)
Filed: 2022-11-09
Fiscal period: fiscal Q3 2022
Accession: 0001493152-22-031108 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PROVECTUS BIOPHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2022-09-30	2,050,453	USD
At 2021-12-31	3,513,356	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2022-09-30	8,909,023	USD
At 2021-12-31	7,700,636	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2022-09-30	-6,858,570	USD
At 2022-06-30	-6,147,087	USD
At 2022-03-31	-5,068,918	USD
At 2021-12-31	-4,187,280	USD
At 2021-09-30	-2,948,643	USD
At 2021-06-30	-2,610,679	USD
At 2021-03-31	-31,615,870	USD
At 2020-12-31	-30,206,357	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2022-09-30	67,030	USD
At 2021-12-31	682,984	USD
At 2021-09-30	254,083	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-713,267	USD	92
2022-01-01 to 2022-09-30	-2,822,030	USD	273
2022-04-01 to 2022-06-30	-1,077,841	USD	91
2022-01-01 to 2022-03-31	-1,030,922	USD	90
2021-07-01 to 2021-09-30	-1,051,259	USD	92
2021-01-01 to 2021-09-30	-4,300,800	USD	273
2021-04-01 to 2021-06-30	-1,579,591	USD	91
2021-01-01 to 2021-03-31	-1,669,950	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	-2,286,682	USD	273
2021-01-01 to 2021-09-30	-2,635,281	USD	273

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	314,890	USD	92
2022-01-01 to 2022-09-30	824,205	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	893,683	USD	273
2021-01-01 to 2021-09-30	2,793,051	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2022-09-30	-248,855,988	USD
At 2021-12-31	-246,033,958	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	419,489,239	shares	92
2022-01-01 to 2022-09-30	419,461,313	shares	273
2021-07-01 to 2021-09-30	409,961,614	shares	92
2021-01-01 to 2021-09-30	405,286,784	shares	273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	0	USD/shares	92
2022-01-01 to 2022-09-30	-0.01	USD/shares	273
2021-07-01 to 2021-09-30	0	USD/shares	92
2021-01-01 to 2021-09-30	-0.01	USD/shares	273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2022-09-30	22,979	USD
At 2021-12-31	31,836	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	3,025	USD	273
2021-01-01 to 2021-09-30	23,688	USD	273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-666,189	USD	92
2022-01-01 to 2022-09-30	-2,744,227	USD	273
2021-07-01 to 2021-09-30	-1,047,231	USD	92
2021-01-01 to 2021-09-30	-3,449,924	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2022-09-30	1,899,415	USD
At 2021-12-31	3,441,957	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2022-09-30	8,824,004	USD
At 2021-12-31	7,700,636	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2022-09-30	1,941,315	USD
At 2021-12-31	1,287,459	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	981,079	USD	92
2022-01-01 to 2022-09-30	3,568,432	USD	273
2021-07-01 to 2021-09-30	1,047,231	USD	92
2021-01-01 to 2021-09-30	3,449,924	USD	273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	580,390	USD	92
2022-01-01 to 2022-09-30	2,068,154	USD	273
2021-07-01 to 2021-09-30	608,653	USD	92
2021-01-01 to 2021-09-30	1,866,776	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2022-09-30	419,497,119	shares
At 2021-12-31	419,447,119	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2022-09-30	241,593,029	USD
At 2021-12-31	241,440,106	USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2022-09-30	-36,752	USD
At 2021-12-31	-34,467	USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

Period	Value	Unit	Days
At 2022-09-30	128,059	USD
At 2021-12-31	39,563	USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

Period	Value	Unit	Days
At 2022-09-30	128,396	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2022-09-30	100,035	USD
At 2021-12-31	91,178	USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-714,508	USD	92
2022-01-01 to 2022-09-30	-2,824,315	USD	273
2021-07-01 to 2021-09-30	-1,051,452	USD	92
2021-01-01 to 2021-09-30	-4,301,277	USD	273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	400,689	USD	92
2022-01-01 to 2022-09-30	1,500,278	USD	273
2021-07-01 to 2021-09-30	438,578	USD	92
2021-01-01 to 2021-09-30	1,583,148	USD	273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	8,857	USD	273
2021-01-01 to 2021-09-30	9,648	USD	273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-47,078	USD	92
2022-01-01 to 2022-09-30	-77,803	USD	273
2021-07-01 to 2021-09-30	-4,028	USD	92
2021-01-01 to 2021-09-30	-850,876	USD	273

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	50,784	USD	273
2021-01-01 to 2021-09-30	64,231	USD	273

Inspect the source

Entity: PROVECTUS BIOPHARMACEUTICALS, INC. / CIK 0000315545
Captured: 2026-09-19T14:56:22.911Z
SEC response SHA-256: 5c46f06a9f23badc21fb49ef63f53fb89ac39f7570babcbf8a64cddf67fb05d2

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000315545.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))